Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies-Reference-Cited by-同舟云学术

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies

Published:2017-12-06 Issue:3 Volume:36 Page:359-368
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Makady Amr^ORCID,van Veelen Ard,Jonsson Páll,Moseley Owen,D’Andon Anne,de Boer Anthonius,Hillege Hans,Klungel Olaf,Goettsch Wim

Funder

None.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-017-0596-z/fulltext.html

Reference35 articles.

1. Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014;6:228.

2. Kumar P, Clark ML. Kumar and Clark's Clinical Medicine, 9th edn. 2012. Elsevier, Canada

3. Azoury C, Lange R. Epidemiology, risk factors, prevention, and early detection of melanoma. Surg Clin N Am. 2014;94:945–62.

4. Makady A, Kalf R, Goettsch W, Lees M. Deliverable D1.6 WP1 case study review: metastatic melanoma. 2016. http://www.imigetreal.eu/Portals/1/Documents/01%20deliverables/Deliverable%20D1.6%20-%20Metastatic%20Melanomav2_website%20version.pdf . Accessed 17 Nov 2017.

5. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587–95.

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance;Journal of Market Access & Health Policy;2024-05-20

2. Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps;Value in Health;2024-05

3. Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries;Future Oncology;2024-04-25

4. Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study;JCO Global Oncology;2024-04

5. Generating and using real-world data: A worthwhile uphill battle;Cell;2024-03